You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma
SBC: NUVOX PHARMA, L.L.C. Topic: 102Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model
SBC: Cytex Therapeutics, Inc. Topic: NIAMSAbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
An Integrated Microarray Printing and Detection System
SBC: BIOSENSING INSTRUMENT INC Topic: 400DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
PLATFORM FOR NEUROCOGNITIVE EVALUATION AND MONITORING
SBC: ENFORMIA INC. Topic: NCICurrent standardized neuropsychological tests are based on decades old paper and pencil methods They lack reliability sensitivity specificity repeatability and require trained neuropsychologists to administer them Their administration in clinical and research settings result in high cost complexity and inconsistent results There is a need and a commercial opportunity for an extensible co ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
An RNA targeted platform for anti flavivirus drug discovery
SBC: Ribometrix LLC Topic: NIAIDSUMMARY Emerging and re emerging mosquito borne flaviviruses cause widespread mortality morbidity and economic burden Options for prevention and treatment of mosquito borne flaviviruses are limited Flavivirus vaccines face unique development challenges no antiviral therapies are available and the mosquito vectors have proven difficult to eradicate Despite vaccines against Yellow Fever and J ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of user-friendly fluorescence based assays for marine toxins
SBC: SEATOX RESEARCH INC Topic: 113ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Enhancing cytarabine efficacy in leukemia through CDK inhibition
SBC: SENEX BIOTECHNOLOGY, INC. Topic: 102Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Peptide based tool for the rapid isolation of quiescent monocytes from peripheral blood
SBC: AFFINERGY, LLC Topic: 102SUMMARY ABSTRACT Dendritic cell DC therapy represents a new and promising immunotherapeutic approach for treatment of advanced stage cancers with DC vaccines already approved for use in advanced prostate cancer and more than DC based vaccines in the clinical development pipeline for other cancers In particular the US market for cancer vaccines including DC based vaccines is set to expan ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel injectable resiquimod formulation for treatment of metastatic cancers
SBC: Curebiotech, Inc. Topic: NCIPROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer causing a large majority of skin cancer related deaths worldwide Recently there have been staggering breakthroughs with the advent of drugs that act on checkpoint inhibitors These are paradigm shifting immunotherapeutic agents not only for melanoma but for cancers in general because they harness the bodyan ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
CRISPR Cas Systems Delivered by Targeted Nanoparticles to Eradicate Herpesvirus Pathogens
SBC: Theragnostic Technologies Inc. Topic: NIAIDAbstract Herpesviruses are chronic pathogens that infect for life there is no cure years since the discovery of the first tumor virus the herpesvirus Epstein Barr virus EBV there exist no specific antivirals for EBV during its latency phase and there are no vaccines The same holds true for most of the other eight human herpesviruses This proposal aims to develop novel tools to eradicat ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health